- Gross revenues increase by 1.3 percent to 3.2 million euros

- EBITDA of +3.8 million euros shows signs of special effects

- Earnings per share rises significantly from -0.08 euros to +0.40 euros

- Liquidity of 3.7 euros offer sufficient freedom of action

curasan AG (ISIN DE0005494538), a leading specialist for medical products in the field of bone and tissue regeneration, can point to the first positive effects of the new distribution strategy presented at the 2015 annual general meeting as reflected in its six-month report published today. The company's gross revenues increased only moderately by 1.3 percent compared to the same period in the previous year to 3.2 million euros, but the expected temporarily weaker development in the core German market was overcompensated by international growth. Revenues in the focal area of the Middle East doubled to nearly 0.2 million euros. The United Kingdom contributed initial revenues to the result for the first time as well.

The expected decline in revenues in Germany is due primarily to the out-licensing of the orthopedic business to our exclusive partner TriMedicales as well as the termination of the sales activities related to the commercial product Cytoplast. Compared to the previous year, this was reflected in the first six months of 2015 in a revenue base reduction by 0.2 million euros. These effects will further reduce the revenue base by another 0.4 million euros in the second half of 2015.

"When the revenue base is adjusted for these, the results of the first six months are very solid," as CEO Michael Schenk explained. "Although these dynamics certainly only reflect base effects, our strategy of tapping fertile ground in selected international regions to foster growth has been reaffirmed".

Earnings before interest, taxes, depreciation, and amortization (EBITDA) rose to +3.8 million euros from -0.4 million euros in the previous year in the wake of the out-of-court settlement reached with distributor Stryker in the second quarter. Earnings per share increased accordingly to +0.40 euros from -0.08 euros in the previous year. At the six-month point, liquidity amounted to 3.7 million euros, which was also reflected in an increase of the equity ratio to a strong 71.8 percent.

"We are well aware that our performance specification still places tough demands on us," Schenk said in summary. "At the same time, we now have sufficient capital reserves to achieve profitability on a sustainable basis under our own steam, even if the path to growth should occasionally be bumpy in the future."

On the basis of a conservative forecast for the full fiscal year 2015, the company expects gross revenues of 6.3 to 6.9 million euros and a net loss of 1.2 to 1.6 million euros adjusted for special effects. With the publication of the interim nine-month report for 2015, the company will provide further details of this forecast.

curasan has scheduled a conference call for analysts and qualified investors at 1:30 p.m. today. Interested parties can register by sending an e-mail to the Investor Relations and Corporate Communications departments.

curasan has made the full report on the first six months of 2015 available as a download on its website under the following link:

www.curasan.de/de/investor_relations/zwischenmitteilungen_halbjahresberichte.php

About curasan AG:
curasan AG develops, manufactures and markets biomaterials and other medical products in the field of bone and tissue regeneration. A pioneer in its industry, curasan is specialized primarily on synthetic bone grafting materials for dental and orthopaedic applications. Numerous patents and a comprehensive list of scientific documentation prove the clinical success of the products and the highly innovative strength of curasan. Surgically active dentists, implantologists and oral, maxillary and dentofacial surgeons, as well as orthopaedics, traumatologists and spinal column surgeons worldwide benefit from the broad range of the premium quality and user-oriented portfolio offered by the technology leader. curasan maintains its own high-tech facilities for research, development and manufacturing in Frankfurt/Main, Germany, which are approved by the Food and Drug Administration (FDA) and other international authorities. In addition to its headquarters, the company has a subsidiary, curasan Inc., in the Research Triangle Park, near Raleigh, N.C., USA.The shares of curasan AG are listed in the General Standard at the Frankfurt Stock Exchange.

Contact:
Ingo Middelmenne
Head of Investor Relations
Tel. +49 6027 40900-45
Fax +49 6027 40900-39
ingo.middelmenne@curasan.de


Andrea Weidner
Head of Corporate Communications
Tel. +49 6027 40900-51
Fax +49 6027 40900-39
andrea.weidner@curasan.de
www.curasan.de